Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$136.64

-0.35 (-0.26%)

, TEVA

Teva

$15.90

-0.455 (-2.78%)

17:01
03/25/19
03/25
17:01
03/25/19
17:01

Oklahoma clears path for J&J, Teva, Purdue to face opioid trial, Reuters reports

The Oklahoma Supreme Court declined to delay a landmark trial set for May in a major lawsuit claiming that OxyContin maker Purdue Pharma along with Johnson & Johnson (JNJ) and Teva (TEVA) helped fuel an opioid abuse and overdose epidemic in Oklahoma, Reuters' Nate Raymond reports. The decision by the state's top court was a win for Oklahoma Attorney General Mike Hunter, whose case is set to be the first to face trial of roughly 2,000 suits nationally aiming to hold opioid makers responsible for contributing to the epidemic, Raymond notes. Hunter's 2017 suit accuses Purdue, J&J, and Teva of engaging in deceptive marketing that downplayed the risks of opioid addiction while overstating the benefits, the author notes. Reference Link

JNJ

Johnson & Johnson

$136.64

-0.35 (-0.26%)

TEVA

Teva

$15.90

-0.455 (-2.78%)

  • 25

    Mar

  • 16

    Apr

  • 25

    Apr

JNJ Johnson & Johnson
$136.64

-0.35 (-0.26%)

02/27/19
CHDN
02/27/19
NO CHANGE
Target $40
CHDN
Buy
MeiraGTx price target raised to $40 from $30 at Chardan
Chardan analyst Gbola Amusa raised his price target for MeiraGTx Holdings (MGTX) to $40 from $30 following Johnson & Johnson's equity stake in the company. MeiraGTx , a top pick for 2019 at Chardan, announced a strategic collaboration on inherited retinal diseases with J&J's Janssen Pharmaceuticals and an $80M private placement, with the investment arm of J&J taking a $40M stake, Amusa tells investors in a research note. The news represents the third announced collaboration or investment by a J&J vehicle in MeiraGTx, the analyst points out. This may signal potential takeover interest by J&J longer term and suggests the pharma giant sees significant value in the inherited retinal diseases market opportunities, contends Amusa. He keeps a Buy rating on MeiraGTx.
03/15/19
BARD
03/15/19
NO CHANGE
BARD
Stryker, Wright Medical best positioned in medical robotics, says Baird
Following meetings at American Academy of Orthopaedic Surgeons this week, Baird analyst Jeff Johnson said that Stryker (SYK) remained the "clear robotics leader," and added that Smith & Nephew (SNN), Zimmer Biomet (ZBH), and to a lesser extent Johnson & Johnson (JNJ) were all "making progress." The analyst came away most positive on Stryker, due to momentum in multiple pipelines, and Wright Medical (WMGI), due to its core business strength and its intriguing pipeline. Johnson has an Outperform rating and $201 price target on Stryker, and Outperform rating and $36 price target on Wright Medical Group.
03/15/19
FBCO
03/15/19
NO CHANGE
FBCO
Outperform
J&J talc risk more than accounted for in current valuation, says Credit Suisse
Credit Suisse analyst Vamil Divan said a $29M jury award to a woman who claimed that asbestos in baby powder led to her development of mesothelioma has brought potential litigation risk for Johnson & Johnson back into the headlines. However, he spoke to Johnson & Johnson and they remain confident in the safety of their product, stating that they plan to appeal and feel there were serious procedural and evidentiary errors made in the trial. Divan, who believes the potential risk from talc cases has been "more than sufficiently accounted for" in the current valuation of J&J shares, also thinks that multiple ongoing cases will hopefully lead to more clarity soon. He keeps an Outperform rating on Johnson & Johnson shares.
03/22/19
ADAM
03/22/19
NO CHANGE
ADAM
Buy
Breast implant panel documents in-line with expectations, says Canaccord
Canaccord analyst Kyle Rose maintains his Buy rating on Sientra (SIEN) following the release of briefing documents ahead of next week's FDA panel meeting to review a range of topics related to the long-term benefits and risks of breast implants, stating that the documents appear to be in-line with expectations and do not appear to raise any materially new or concerning questions or data. However, given the warning letters sent this week to Sientra and J&J's (JNJ) Mentor unit, Rose said he expects the FDA to "take a strong tone" during the panel about the responsibility to support the collection and analysis of relevant safety and efficacy clinical data. Other makers of breast implants include Allergan (AGN) and Establishment Labs (ESTA).
TEVA Teva
$15.90

-0.455 (-2.78%)

03/07/19
UBSW
03/07/19
INITIATION
Target $22
UBSW
Buy
Teva reinstated with a Buy at UBS
UBS analyst Navin Jacob reinstated coverage of Teva Pharmaceutical with a Buy rating and $22 price target. The U.S. generic industry is on a path to recovery, Jacob tells investors in a research note, citing his firm's generic price erosion tracker data. The analyst sees 30% potential upside and views Teva's 2019 guidance as a "hiccup."
03/07/19
03/07/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Five Below (FIVE) initiated with an Outperform at Oppenheimer. 2. Teva (TEVA) reinstated with a Buy at UBS. 3. Chiasma (CHMA) initiated with an Overweight at Cantor Fitzgerald. 4. Monster Beverage (MNST) and Constellation Brands (STZ) were initiated with an Outperform at Credit Suisse, while Procter & Gamble (PG), Coca-Cola (KO), and Church & Dwight (CHD) were initiated with a Neutral, and PepsiCo (PEP), Colgate-Palmolive (CL), and Clorox (CLX) initiated with an Underperform at Credit Suisse. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/13/19
WELS
03/13/19
NO CHANGE
Target $68
WELS
Market Perform
Wells says generic risk, not Purdue news, bringing down Emergent shares
Wells Fargo analyst David Maris "completely" disagrees with the view that shares of Emergent BioSolutions (EBS) are weak today on news of Purdue Pharma's nalmefene injection receiving fast track designation from the FDA. Maris notes that none of his clients have raised this as a potential issue and that, as an injection, Purdue's pproduct is not comparable to Emergent's nasal naloxone. An injection is not practical for the emergency medical technician and at home market, where most of Narcan is used, Maris tells investors in a research note. For example, Amphastar (AMPH) is a leader in the injectable market, and the vast majority of its use is in the hospital setting, the analyst points out. Rather, Maris attributes the recent selloff in Emergent BioSolutions to worries about the potential introduction of a generic version of Narcan. Teva (TEVA) has had a tentative approval for generic Narcan for some time, and its 30 month stay is over today, meaning that Teva could launch at risk from this point forward, Maris writes. As of now, there is no clear indication whether Teva will launch or not, he adds. While the analyst is not expecting an at-risk Narcan launch, he believes the risk of such an event is largely reflected in the shares given today's decline. Nonetheless, Maris keeps a Market Perform rating on Emergent with a $68 price target. The stock in afternoon trading is down 9%, or $4.98, to $52.00.
03/19/19
RHCO
03/19/19
INITIATION
Target $17
RHCO
Hold
Teva initiated with a Hold at SunTrust
SunTrust analyst Gregg Gilbert initiated Teva with a Hold rating and a price target of $17, saying that while the new CEO Kare Schultz led a cost base restructuring effort and trying to turn around the U.S. generics business, those positive are likely factored into the stock price. The analyst adds that the company's recent delay in expecting to achieve its deleveraging target "may make existing holders anxious and potential holders more patient."

TODAY'S FREE FLY STORIES

GMRE

Global Medical REIT

$13.02

-1.065 (-7.56%)

09:47
12/11/19
12/11
09:47
12/11/19
09:47
Hot Stocks
Global Medical REIT falls -8.0% »

Global Medical REIT is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

UNFI

United Natural Foods

$8.62

-1.26 (-12.75%)

09:47
12/11/19
12/11
09:47
12/11/19
09:47
Hot Stocks
United Natural Foods falls -13.0% »

United Natural Foods is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 18

    Dec

GME

GameStop

$5.62

-0.88 (-13.54%)

09:47
12/11/19
12/11
09:47
12/11/19
09:47
Hot Stocks
GameStop falls -14.0% »

GameStop is down -14.0%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

SBGL

Sibanye-Stillwater

$8.94

0.44 (5.18%)

09:47
12/11/19
12/11
09:47
12/11/19
09:47
Hot Stocks
Sibanye-Stillwater rises 5.3% »

Sibanye-Stillwater is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PACK

Ranpak Holdings

$5.95

(0.00%)

09:47
12/11/19
12/11
09:47
12/11/19
09:47
Hot Stocks
Ranpak Holdings rises 5.5% »

Ranpak Holdings is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

CHH

Choice Hotels

$102.62

5.22 (5.36%)

09:47
12/11/19
12/11
09:47
12/11/19
09:47
Hot Stocks
Choice Hotels rises 5.4% »

Choice Hotels is up 5.4%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:45
12/11/19
12/11
09:45
12/11/19
09:45
General news
FX Action: USD-JPY »

FX Action: USD-JPY has…

AAPL

Apple

$268.62

(0.00%)

09:44
12/11/19
12/11
09:44
12/11/19
09:44
Recommendations
Apple analyst commentary  »

Apple price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VREX

Varex Imaging

$29.96

(0.00%)

09:44
12/11/19
12/11
09:44
12/11/19
09:44
Conference/Events
Varex Imaging management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

VECO

Veeco

$13.88

(0.00%)

09:42
12/11/19
12/11
09:42
12/11/19
09:42
Conference/Events
Veeco management to meet with Benchmark »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

PLAY

Dave & Buster's

$40.07

(0.00%)

09:41
12/11/19
12/11
09:41
12/11/19
09:41
Recommendations
Dave & Buster's analyst commentary  »

Dave & Buster's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$29.85

(0.00%)

, SQ

Square

$65.82

(0.00%)

09:41
12/11/19
12/11
09:41
12/11/19
09:41
Hot Stocks
Dorsey: Twitter funding team to develop decentralized standard for social media »

Twitter (TWTR) CEO Jack…

TWTR

Twitter

$29.85

(0.00%)

SQ

Square

$65.82

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Feb

  • 26

    Feb

BA

Boeing

$347.86

(0.00%)

09:41
12/11/19
12/11
09:41
12/11/19
09:41
Conference/Events
House Transportation & Intrastructure Committee to hold a hearing »

The Committee holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

URBN

Urban Outfitters

$27.33

(0.00%)

, JBLU

JetBlue

$18.89

(0.00%)

09:40
12/11/19
12/11
09:40
12/11/19
09:40
Options
Unusually active option classes on open December 11th »

Unusual total active…

URBN

Urban Outfitters

$27.33

(0.00%)

JBLU

JetBlue

$18.89

(0.00%)

CHWY

Chewy

$25.55

(0.00%)

ATVI

Activision Blizzard

$55.94

(0.00%)

BA

Boeing

$347.86

(0.00%)

PTON

Peloton

$32.65

(0.00%)

HD

Home Depot

$215.84

(0.00%)

PCG

PG&E

$12.33

(0.00%)

CMCSA

Comcast

$42.77

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 13

    Dec

  • 07

    Jan

  • 25

    Feb

09:40
12/11/19
12/11
09:40
12/11/19
09:40
General news
The U.S. November CPI report »

The U.S. November CPI…

VCYT

Veracyte

$29.00

0.46 (1.61%)

09:36
12/11/19
12/11
09:36
12/11/19
09:36
Conference/Events
Veracyte management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 16

    Dec

09:34
12/11/19
12/11
09:34
12/11/19
09:34
Conference/Events
Senate Commerce, Science & Transportation Committee holds executive session »

The Committee holds an…

ROAD

Construction Partners

$16.72

-3.84 (-18.68%)

09:33
12/11/19
12/11
09:33
12/11/19
09:33
Recommendations
Construction Partners analyst commentary  »

Construction Partners…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRUP

Trupanion

$33.89

0.02 (0.06%)

09:33
12/11/19
12/11
09:33
12/11/19
09:33
Conference/Events
Trupanion management to meet with Lake Street »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

THTX

Theratechnologies

$3.05

-0.01 (-0.33%)

09:33
12/11/19
12/11
09:33
12/11/19
09:33
Upgrade
Theratechnologies rating change  »

Theratechnologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKER

Akers Biosciences

$2.94

0.03 (1.03%)

09:32
12/11/19
12/11
09:32
12/11/19
09:32
Hot Stocks
Akers Biosciences regains compliance with Nasdaq listing standards »

Akers Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Dec

SPB

Spectrum Brands

$61.63

-1.44 (-2.28%)

09:31
12/11/19
12/11
09:31
12/11/19
09:31
Conference/Events
Spectrum Brands management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

RMAX

RE/MAX Holdings

$39.09

0.24 (0.62%)

09:29
12/11/19
12/11
09:29
12/11/19
09:29
Conference/Events
RE/MAX Holdings management to meet with Craig-Hallum »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

PLPRF

Plus Products

$0.00

(0.00%)

09:28
12/11/19
12/11
09:28
12/11/19
09:28
Hot Stocks
Plus Products transitions to HERBL as primary California distribution partner »

Plus Products announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$146.12

-0.07 (-0.05%)

09:28
12/11/19
12/11
09:28
12/11/19
09:28
Periodicals
Disney+ eclipses 22M mobile downloads, CNBC reports »

Disney+ has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.